Janus Henderson Group PLC Has $12.60 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Janus Henderson Group PLC grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 74.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 713,911 shares of the company’s stock after purchasing an additional 305,397 shares during the period. Janus Henderson Group PLC owned about 1.52% of Enliven Therapeutics worth $12,604,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AJOVista LLC bought a new stake in Enliven Therapeutics during the 4th quarter worth about $28,000. China Universal Asset Management Co. Ltd. bought a new position in Enliven Therapeutics in the fourth quarter valued at approximately $66,000. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $167,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Enliven Therapeutics by 17.8% in the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $24.70 on Friday. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $27.67. The firm has a 50 day moving average price of $22.84 and a two-hundred day moving average price of $19.49.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

ELVN has been the topic of a number of recent analyst reports. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price for the company. Finally, Mizuho initiated coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective on the stock.

Insider Activity

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total transaction of $278,160.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Rishi Gupta sold 1,033,300 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $22.14, for a total value of $22,877,262.00. Following the sale, the director now owns 254,814 shares of the company’s stock, valued at $5,641,581.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,155,148 shares of company stock worth $25,857,771. Corporate insiders own 29.20% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.